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Osteoporosis (OP) risk factor assessment and bone mineral density (BMD) testing are fre-
quently omitted at baseline in aromatase inhibitor (AI) studies, which may lead to misinter-
pretation of AI associated bone loss. The present study describes bone health of South
African postmenopausal women of predominantly Mixed Ancestry, prior to AI treatment.
Methods
This descriptive baseline study, nested in a prospective AI cohort study, included postmeno-
pausal women with endocrine sensitive breast cancer, aged 50 to 80 years. A baseline
questionnaire documented demographic-, medical-, lifestyle- and fracture history. Body
weight was assessed clinically, and body composition and BMD measured via dual energy
absorptiometry (DXA). Data was analysed in STATA 14 using descriptive and inferential
statistics.
Results
101 participants were recruited, with a mean age of 61±7 years. Nearly a third (n = 32) of
women at baseline fulfilled global criteria for bone protection (BMD T-score�-2SD (n = 18);
BMD T-score -1.5SD to < -2SD with risk factors (n = 14). Lower body weight, body mass
index (BMI), fat mass index and lean mass index were significantly associated with the par-
ticipants with a BMD measurement in keeping with a diagnosis of OP (p <0.001). Low vita-
min D was present in 93% of the cohort tested (n = 95), whilst deficient vitamin D status
(<20ng/ml) was documented in 52 women (55%).
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Conclusions
In this study, a third of postmenopausal women considered for AI therapy fulfilled interna-
tional criteria for bone protective pharmacological intervention. This emphasizes the need
for clinical risk and BMD assessment in postmenopausal breast cancer patients at baseline.
Body composition and bone health associations highlight bone fragility associated with
lower body weight.
Introduction
The increased risk for osteoporosis in postmenopausal women relates to physiological changes
in the ageing female body. Osteoporosis (OP) can cause severe impairment of function and
quality of life in elderly women due to the increased fracture risk, especially of the spine and
hip [1,2]. Bone mineral density (BMD) measured by dual energy X-ray absorptiometry (DXA)
is a two-dimensional measure of mineral content in specific skeletal regions [3]. It evaluates
BMD changes over time and can assess response to therapeutic interventions [4,5]. The risk of
fracture increases with a decline in BMD [1,6].
Endocrine treatment is indicated for estrogen receptor (ER) positive breast cancers.
Tamoxifen, a selective estrogen receptor modulator has been used to treat endocrine respon-
sive breast cancer for decades [7]. It protects against accelerated postmenopausal bone loss, by
maintaining selective estrogenic effects on skeletal tissue [8]. Currently, aromatase inhibitors
(AIs) are the gold standard in the treatment of endocrine sensitive breast cancer with an
improved clinical outcome compared to Tamoxifen [9,10].
In postmenopausal breast cancer patients, aromatase enzyme inhibition decreases the already
low levels of estrogen by blocking the conversion of androgen precursors to estrogen [11,12].
Numerous studies have documented accelerated bone loss and facture risk in postmenopausal
women on AI therapy, affecting predominantly the axial skeleton [7,9]. The most pronounced
loss is noted in the first two years of AI treatment and in early menopause (< 4 years).
Many conventional risk factors for the development of OP have been identified [13]. Age,
gender, genetic predisposition and ethnic origin represent the most important non-modifiable
risk factors. Modifiable factors such as low body weight, sedentary lifestyle, poor calcium
nutrition and deficient vitamin D levels, smoking and alcohol excess, may also impact on bone
density. Body weight is one of the most important determinants of BMD at most skeletal sites
in women of all ethnicities [13,14].
In randomised controlled trials of AIs, the baseline state of BMD was not always reported.
Similarly, conventional risk factors for fracture were not consistently quantified and the preva-
lence of osteoporotic fractures prior to AI therapy remains unknown [15]. The presence of
conventional risk factors for osteoporosis and baseline BMD must be considered to accurately
calculate the fracture risk attributable to AI therapy.
The study describes the baseline bone health status, prior to initiation of AI’s, in a multi-ethnic
postmenopausal cohort with endocrine responsive breast cancer, resident in the Western Cape
Province of South Africa. The associations between BMD and body composition as well as lifestyle
factors, known to potentially adversely affect bone mineral status, were examined.
Materials and methods
Study population
This descriptive study, nested within a larger prospective cohort study was conducted at the
tertiary breast clinic of Tygerberg Hospital, affiliated to the University of Stellenbosch.
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Postmenopausal women with newly diagnosed, endocrine sensitive breast cancer, stage 0-III
were eligible for study entry. All 50–80 year old women were consecutively enrolled from
August 2014 until February 2017. Race determination was made by self-declaration. Patients
with known metabolic bone disease, and those with diseases (other than breast cancer), or
medication known to adversely affect BMD were excluded from entry. The research was
approved by the Ethical Review Board of the Faculty of Medicine, University of Stellenbosch
(S13/05/103).
Demographics
A demographic questionnaire administered at baseline, included age, family medical history,
personal health, lifestyle, reproduction, falls and fractures. Lifestyle questions included the use
of alcohol, smoking and activity level. The use of hormonal contraception and years since
menopause (YSM) were documented. A history of prior fragility fractures, fall propensity and
prolonged immobilization (>1 month) [13] was obtained.
Anthropometry
Basic anthropometric measurements (weight, height, waist and hip circumference) were
taken. Body mass index (BMI) values were divided into weight categories according to the
World Health Organisation’s (WHO) classification [16].
Densitometry
The DXA Hologic Discovery-W, S/N 70215; software Version 13.1 was employed to measure
BMD and body composition. During the course of the study, coefficients of variation for BMD
were<1.5%. The availability of a single and experienced DXA technician for the duration of
the study is noteworthy. It ensured an excellent performance and a low intra-operative vari-
ability (<1%) of reported BMD measurements at all skeletal sites in patients initiated on AI-
therapy.
Body composition
Whole body DXA was used to measure and calculate total fat percentage, fat mass index
(FMI), lean mass index (LMI), appendicular skeletal muscle mass as well as an android/gynoid
fat ratio. Fat mass and lean mass measured by DXA are normalized for height to calculate a
FMI (fat/height2), a measure of obesity and a lean mass/height2 as an index of total muscle
mass. The appendicular skeletal muscle mass normalised for height2, is a good surrogate
marker of sarcopenia, if found to be low. No local normative data for DXA measured body
composition exist. The National Health and Nutrition Examination Survey (NHANES) refer-
ence dataset was thus used [16]. In the present NHANES database, fat comprises approxi-
mately 38% of body weight in females at age 25 years and is thus regarded as the normal
reference value for our study. The FMI was used to categorize participants into weight classes
similar to BMI (low/normal fat, excess fat, obese and morbidly obese]. The normal FMI range
is 5–9 kg/m2, excess fat 9.1–13 kg/m2, obese 13.1–21 kg/m2 and morbid obesity indicated by a
FMI in excess of 21 kg/m2. LMI and appendicular lean mass/height2 was categorized as being
2SD below or above expected with the cut-off values being 12.5 kg/m2 and 4.36 kg/m2,
respectively.
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Bone mineral density
Femoral neck (FN), total hip (TH) and lumbar spine (LS) BMD were measured. No normative
data for South African women of mixed or black race exist. We therefore, as currently recom-
mended, used a uniform normative database for white women to calculate T-scores and to
define osteopenia and osteoporosis for all ethnicities. A lateral vertebral assessment (LVA)
detected prevalent morphometric vertebral fractures.
Biochemistry
Morning blood samples were drawn to evaluate calcium homeostasis (serum calcium, phos-
phate, parathyroid hormone (PTH) and 25-OH Vitamin D levels) and to assess biochemical
bone turnover (serum bone specific Alkaline Phosphatase (bALP) and Beta-CrossLaps/serum
assay). Bone specific Alkaline Phosphatase (bALP) was measured with the Beckman Coulter
Unicel DXI 800, a one-step immunoenzymatic assay. The normal reference range for this spe-
cific bALP assay in postmenopausal women is� 22mcg/L. Beta-CrossLaps testing was per-
formed using the Roche Cobas 6000 e601 analyzer and the Roche Beta-CrossLaps assay, a
2-site immunometric (sandwich) assay using electrochemiluminescence detection. This assay
specifically detects crosslinked isomerized type I collagen fragments, independent of the nature
of the crosslink. The upper range of normal for postmenopausal women is set at 1008 pg/ml.
Bone turnover markers are frequently used in clinical trials and provide valuable information
on the efficacy of osteoporotic treatments, but their predictive value is limited by their biologi-
cal variation and they are not routinely used for individualized patient care and diagnosis.
Statistical analyses
Data management and analysis were conducted in STATA 14. Descriptive statistics were used
to summarise the data including baseline characteristics and outcomes. Continuous data were
tested for normality using descriptive statistics (e.g. histograms) where normally distributed
data were presented as means and standard deviations or as medians and interquartile ranges
(IQR), for non-normally distributed data. Categorical data were presented as proportions and
95% confidence intervals. The associations between biological parameters and BMD were
determined using one-way ANOVA and chi2 tests. To account for confounding, significant
univariate predictors were included in a final multinomial logistic regression model at p<0.2
An alpha of 0.05 was considered statistically significant. Associations were reported as relative




A hundred-and-one postmenopausal participants were enrolled with a mean age of 61±7
years. Nearly half (n = 48) the women were 50–59 years of age, with only a minority of the
cohort being 70 years and older (10%). Eighty-two percent of the study population were of
Mixed Ancestry, reflecting the hospital’s reference population. Caucasians represented 13.4%
of the total cohort and only two Black and three Indian women were included. Demographics
and lifestyle data are presented in Table 1.
Nearly half of the study population (42%) smoked at some stage in their lives and 28% of
women were current smokers. Alcohol consumption was minimal with abstinence reported
by 79%. No intake in excess of 7 units per week was reported. Most women lead a moderately
active lifestyle with indoor and outdoor activities documented in 80%. No falls were reported,
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seven women sustained a previous non-vertebral fracture and one participant reported a fam-
ily history of osteoporosis. Menopause occurred at a mean age of 48±5 years with a short dura-
tion (�5years) in 21%. Hormonal contraception was used by 49 women, 19 of whom used an
injectable progesterone-only preparation only.
Mineral homeostasis, calciotropic hormones and biochemical bone
turnover markers
Normal vitamin D status was only documented in 7% of the cohort. Insufficient vitamin D lev-
els (20-30ng/ml) were present in 38% (n = 36), whilst deficient vitamin D status (<20ng/ml)
was documented in 55% (n = 52). Bone disease caused by vitamin D deficiency is usually asso-
ciated with values below 10-12ng/ml. This severe deficiency was only evident in two partici-
pants, of whom both had a normal BMD. Despite the almost universal 25-OH-Vitamin D
Table 1. Summary of lifestyle and menstrual data of breast cancer patients at baseline.
Clinical characteristics (n = 101)
Age (years) 61 ± 7
• 50–59 yrs 48 (48%)
• 60–69 yrs 43 (43%)
• 70 yrs+ 10 (10%)
Smoking
• ever 42 (42%)
• current 28 (28%)
Alcohol
• abstain 79 (79%)
• 1–7 units per week 22 (22%)
• >7 units per week 0
Activity level
• Indoors 20 (20%)
• Indoors and Outdoors 81 (80%)
Falls in last year
• Any fall 0
Clinical fractures
• non-vertebral 7 (7%)
Family history of OP
• positive 1 (1%)
Age at menopause (years) 48 ± 5 years
Duration of menopause (n = 72) 12 ± 8 years
• 0–4 yrs 15 (21%)
• 5–10 yrs 15 (21%)
• > 10 yrs 42 (58%)
Hot Flashes
• ever 64 (63%)
Hormonal contraception (ever)
• Depo-Provera 19 (19%)
• OCP 30 (30%)
Values for age, age at menopause and duration of menopause expressed as mean ± SD, rest of data expressed as n
(%). Cohort n = 101 for all clinical characteristics tabulated unless otherwise specified. OP = osteoporosis, OCP =
oral estrogen containing contraceptive preparation
https://doi.org/10.1371/journal.pone.0214153.t001
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deficiency, only 24 subjects (25%) had secondary hyperparathyroidism. Bone specific alkaline
phosphatase (n = 98; range 4.4–26.5mcg/L; marginally abnormal values in 4 participants 23.6,
24.3, 24.3 and 26.5mcg/mL) and β-cross laps (n = 70; range 90–1340 pg/mL; one abnormal
value of 1340 pg/mL) were normal in 96% and 99% of the cohort respectively. Biochemical
bone turnover assessment ruled out any significant baseline increase in bone turnover in
almost all study participants.
Body composition
Clinical and densitometric parameters of body composition are tabulated in Table 2. A con-
cerning 85% of women were overweight, with 59% in the obese categories of WHO-BMI [16].
Table 2. Body composition in postmenopausal breast cancer patients at baseline.
Clinical parameters (n = 101) Category values Measurement
Weight (kg) 81.2 ± 19.4
Height (cm) 158.6 ± 6.0
BMI (kg/cm2) 32.4 ± 7.8
BMI weight categories
• Low/normal body weight � 25 kg/m2 15 (15%)
• Overweight 25.1–29.9 kg/m2 26 (26%)
• Obesity 30–39.9 kg/m2 42 (41%)
• Morbid obesity �40 kg/m2 18 (18%)
Waist circumference (cm) 102.1 ± 15.8
Waist/Hip circumference (cm) 0.9 ± 0.1
• > 0.85� 79 (78%)
Densitometric parameters (n = 101) Category values Measurement
Mean Total Body Fat Mass (%) 45 ± 6
• Normal � 38% 6 (6%)
• Increased > 38% 95 (94%)
Mean Fat Mass Index (FMI) (kg/m2) 14.6 ± 4.9
• Normal 5–9 11 (11%)
• Excess fat 9.1–13 30 (30%)
• Obese 13.1–21 53 (52%)
• Morbid obesity >21 7 (7%)
Mean Lean Mass Index (LMI) (kg/m2) 16.7± 2.8
• Above third centile (>2SD) � 12.5 98 (97%)
• Normal range < 12.5 3 (3%)
Mean Appendicular Lean mass/height2 (kg/cm2) 7.2 ± 5.5
• Above third centile (>2SD) � 4.36 99 (98%)
• Normal range < 4.36 2 (2%)
Mean Android/Gynoid ratio 1.0 ± 0.1
• Gynoid dominant fat distribution � 1 44 (44%)
• Android dominant fat distribution (visceral) > 1 57 (56%)
Body composition evaluated clinically and with DXA. Mean values presented as means ± standard deviation unless
otherwise specified. Cohort sub-classified into WHO weight categories based on BMI and percentage of cohort with
waist/hip circumference indicative of metabolic syndrome [16,17] noted�. Cohort also sub-classified into Fat Mass
Index classification ranges in accordance with BMI weight categories. LMI and appendicular lean mass/height2 divided
into categories below and above the third centile (2SD) for specific measurement in young NHANES females. All
densitometric measured categories defined based on NHANES data base for young normal females within normal BMI
range [16] Data expressed as n(%) of subjects within all weight categories.Bone mineral density
https://doi.org/10.1371/journal.pone.0214153.t002
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A waist/hip ratio in excess of 0.85 was present in the majority (78%). Densitometric assessment
of body composition was in accordance with our clinical assessment. The mean total body fat
mass percentage (45 ± 6%) and the mean fat mass index (FMI) (14.6 ± 4.9kg/m2) was signifi-
cantly above normal. A high FMI was documented in 89% and a FMI indicative of obesity was
present in 59% of the cohort.
Lean mass appeared well maintained. A significantly decreased lean mass index (LMI)
(< 12.5 kg/m2) and appendicular lean mass/ height2 (<4.36kg/cm2) indicative of a loss of mus-
cle strength, was documented in only three and two subjects respectively.
The clinically determined BMI and the densitometric FMI were remarkably similar in the
classification of women within the different weight categories. In the normal to low BMI cate-
gory, three women had a FMI marginally above 9 (10.3 kg/m2 in two subjects and 10.5 kg/m2
in the third subject), and only four women in the obese category, had a FMI below 13.1 kg/m2
(6.7%).
Baseline BMD was assessed at the lumbar spine in all participants (n = 101) and in 100
women at the femoral neck and total hip region (bilateral hip replacement in one participant)
(Table 3). BMD is expressed as an absolute density in g/cm2 and the deviation from expected
peak value for the specific individual i.e. as a T-score to determine the patient’s specific BMD
category as either within the normal, osteopenic or osteoporotic range[18]. The mean BMD at
all the measured sites for the total cohort was within the normal range (T-scores less -1 SD
below expected peak).
A normal BMD at all measured sites was documented in 48 (48%) of the total study popula-
tion. A concerning 52% of participants thus displayed osteopenia or osteoporosis at one or
more measured sites i.e. BMD T-score deviations of -1 SD or more. BMD in keeping with oste-
oporosis at one or more sites was present in 14 women (14%) prior to any hormonal interven-
tion for breast cancer. Osteopenia and osteoporotic range BMD were most prevalent in the
axial skeleton (Table 3).
DXA-LVA indicated mild morphometric vertebral abnormalities in 15 women. Conven-
tional lumbosacral X-rays excluded significant vertebral compression (�20% of vertebral
height) in all these women.
Clinical characteristics, body composition and biochemistry within BMD
subcategories (normal, osteopenia, osteoporosis)
Chronological age was similar in the BMD subcategories. Years since menopause (YSM)
increased with worsening bone profile, with a mean duration of menopause 5 years longer in
those with OP compared to the normal BMD subgroup. No significant association between
Table 3. Bone Mineral Density in postmenopausal breast cancer patients at baseline.
BMD Lumbar Spine BMD (n = 101)) Femoral Neck BMD (n = 100) Total Hip BMD (n = 100)
Absolute value g/cm2 0.982 ± 0.171 0.780 ± 0.119 0.913 ± 0.142
T-score -0.5 ± 1.6 -0.65 ± 1.1 -0.2 ± 1.1
• Normal 58 (58%) 61 (61%) 75 (75%)
• Osteopenia (< −1.0 > -2.5) 30 (30%) 32 (32%) 21 (21%)
• Osteoporosis (� -2.5) 13 (13%) 7 (7%) 3 (3%)
• High BMD (> 2.5) 3 (3%) 1 (1%) 1 (1%)
Absolute BMD values and T-scores at all the measured sites are presented as means ± standard deviation for the total study population. The cohort is then sub-classified
into WHO-BMD categories [19]. Number of patients and percentage of study population within subgroups for all measured sites is noted. Normal subgroup also include
patients with measured BMD T-score more than + 2.5SD
https://doi.org/10.1371/journal.pone.0214153.t003
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YSM and BMD subgroups was noted (p = 0.14). In all the patients with OP, in whom the dura-
tion of menopause was documented (n = 6), YSM exceeded 5 years.
Body composition differed amongst BMD subcategories, with significantly lower total body
weight, BMI, FMI, total fat percentage and LMI documented in the women with OP (p<0.001;
Table 4). Fifty percent of women (7/14) with baseline OP had a low/normal BMI of�25 kg/
m2. The rest were overweight (n = 4) or obese (n = 3). No morbidly obese woman was
osteoporotic.
The mean 25-OH-Vitamin D (p = 0.290) and PTH levels (p = 0.221) were similar in the
BMD subcategories (Table 4). Nearly half (46%) of women with OP had compensatory sec-
ondary hyperparathyroidism, but a significant adverse BMD effect in ascending PTH tertials,
could not be demonstrated (p = 0.720).
When looking at BMD subcategories at specific bone sites i.e. at the femur neck, total hip
and lumbar spine, a similar trend was noted for clinical characteristics, body composition and
biochemistry relationships compared to the composite BMD. BMD at all measured sites
increased significantly with increasing BMI based on WHO subcategories as demonstrated in
Fig 1.
Multinomial regression adjusting for known confounders indicated PTH (RR 1.61, 95% CI
1.15–1.25) and LMI (RR 0.3, 95% CI 0.11–0.85) were significantly associated for OP compared
to normal bone status (Table 5).
Table 4. Body composition within DXA-BMD subcategories.








Age (yrs) 59 ± 6 62 ± 7 64 ± 8 0.074
Years since menopause (yrs) 11 ± 9 14 ± 3 16 ± 6 0.14
Body composition
Total body weight (kg) 86.6 ± 17.3 79.5 ± 19.2 63.8 ± 15.4 <0.001
BMI (kg/m2) 34.3 ± 6.4 31.7 ± 8.4 25.8 ± 6.2 <0.001
Waist/Hip ratio 0.91 ± 0.06 0.88 ± 0.08 0.91 ± 0.14 0.48
Total body fat (%) 46.9 ± 5.0 44.9 ± 6.6 41.6 ± 5.9 0.144
FMI (kg/m2) 15.0 ± 4.3 14.0 ± 4.9 10.5 ± 3.6 <0.001
LMI (kg/m2) 17.6 ± 2.5 16.3 ± 2.9 14.2 ± 1.9 <0.001
Appendicular lean mass (kg/m2) 8.1 ± 7.6 6.6 ± 1.1 5.5 ± 1.1 0.19
Biochemistry
Vitamin D (ng/ml) 19.8 ± 5.8 18.9 ± 6.3 22.1 ± 8.4 0.290
• Total n 49 35 11
• Sufficient [>30ng/ml] n (%) 3 (6%) 2 (5%) 2 (18%)
• Insufficient [20-30ng/ml] n (%) 21 (43%) 12 (34%) 3 (27%)
• Deficient: [< 20ng/ml] n (%) 25 (51%) 21 (60%) 6 (54%)
PTH (pmol/L) 5.54 ± 2.87 5.10 ± 1.99 6.77 ± 4.36 0.221
• Total n 48 36 11
• normal [1.6–6.9 pmol/L] n (%) 36 (75%) 29 (80%) 6 (54%)
• elevated n (%) 12 (25%) 7 (20%) 5 (46%)
All values expressed as means ± SD, unless otherwise specified. Yrs = years; BMI = body mass index; FMI = fat mass index; LMI = lean mass index; BMD = bone
mineral density. BMD subcategories refers to DXA BMD T-score: normal = less than 1SD below norm, osteopenia = -1 to -2.49 SD below normal and osteoporosis =
�-2.5 SD below norm. p- value significant at < 0.05 for continuous comparison normal BMD versus osteopenia and osteoporosis subgroups.
https://doi.org/10.1371/journal.pone.0214153.t004
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Discussion
In this study a concerning 14% of women had osteoporosis and half of the cohort were osteo-
penic prior to any intervention. Body composition, especially lean mass, was positively associ-
ated with bone mass at all measured sites and the risk of being osteoporotic less with
increasing Lean Mass Index (p<0.0001). Clinical and densitometric measures of body weight
and composition were universally lowest in women with OP (p<0.001).
Only seven participants had sufficient 25-OH Vitamin D levels with compensatory, second-
ary hyperparathyroidism documented in more women with OP (45%) than in the rest of the
cohort (23%).
The addition of AIs in the endocrine treatment of breast cancer compounds OP risk. The
International Osteoporosis Foundation Bone and Cancer Working Group indicates that
women on AI therapy for breast cancer, experience a two to four-fold increase in bone loss
[20]. Clinical trials show an approximately 10% increase in absolute fracture risk for women
on AI therapy [12,18]. The fracture incidence in women with breast cancer on AI therapy was
reported to be 18–20% after five years of follow-up [21]. It is thus essential to delineate BMD
and clinical risk factors for bone loss and fracture at the start of AI treatment to allow for risk
stratification and appropriate preventative measures. Breast cancer treatment seeks not only to
prolong survival, but also to limit side effects [12,22].
BMD is viewed as the most robust indicator of fracture risk in untreated patients [3]. Ethnic
differences in bone mass and fracture risk have been described globally, but established data
Fig 1. Bone mineral density within the WHO-BMI subcategories.
https://doi.org/10.1371/journal.pone.0214153.g001
Table 5. Crude versus adjusted predictors (reporting relative risk) for BMD status at baseline.
Crude RR Adjusted RR
Predictors of BMD Osteopenia Osteoporosis Osteopenia Osteoporosis
BMI 0.95 (0.83–1.01) 0.82 (0.77–0.92) 1.14 (0.90–1.44) 1.24 (0.80–1.93)
Fat mass index 0.91 (0.83–1.00) 0.74 (0.62–0.88) 0.87 (0.66–1.14) 0.73 (0.44–1.21)
Lean mass index 0.82 (0.69–0.98) 0.54 (0.35–0.75) 0.70 (0.47–1.03) 0.30� (0.11–0.85)
PTH 0.93 (0.79–1.10) 1.13 (0.92–1.38) 0.98 (0.81–1.17) 1.61� (1.15–2.25)
Comparison of predictors of normal BMD. RR (95% CI)
�p-value significant (adjusted only) at <0.05.
https://doi.org/10.1371/journal.pone.0214153.t005
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mostly limited to black and white populations [2,23]. More than 80% of our study population
were of Mixed Ancestry, a population subgroup in whom BMD and fracture prevalence is
largely unknown. In the only reported data from South Africa, BMD measurements in women
of Mixed Ancestry were similar to whites at all measured sites [24]. Extrapolated from densito-
metric studies, fracture risk is thus expected to be similar in white women and those of Mixed
Ancestry. No formal study looking at fracture prevalence in women of Mixed Ancestry in SA
has, however, been conducted to date and the prevalence of vertebral fractures in this ethnic
group thus remains unknown. Such knowledge will facilitate management strategies for osteo-
porosis and fractures across all ethnic groups and in the post-menopausal woman treated for
breast cancer [25].
The lowered BMD in more than half of our cohort at baseline is concerning. This argues for
routine BMD measurements in postmenopausal women of Mixed Ancestry with breast cancer
considered for AI therapy. In the majority of our subjects, significant bone loss was confined
to the axial skeleton, inferring an increased vertebral fracture risk. Global consensus recom-
mends that all women with a BMD T-score� -2 SD at any measured site, should undergo
bone protective therapy [20]. Additionally, patients with a BMD T-score between -1.5SD and
-2SD with one or more additional risk factors for bone loss, should also be considered for
treatment. These include age above 65 years, smoking, a family history of hip fracture or a per-
sonal history of fragility as well as low body weight and a course of steroid therapy in excess of
3 months.
Based on these recommendations, eighteen women in our cohort (18%) warranted bone
specific therapy based on BMD per se. An additional fourteen participants also required pro-
tection as they had a BMD T-score between -1.5 SD and -2 SD and at least one conventional
risk factor for bone loss. Nearly one-third (32%) of women at baseline thus fulfilled the criteria
for bone specific intervention.
Obesity is associated with higher BMD in postmenopausal women and slower rates of bone
loss at the hip and spine. Eighty-five percent of our cohort was overweight, a factor that may
afford bone protection. In continuous comparison, the relationship between fat mass indices
and lean mass indices with BMD measurements, were similar in this study. Fat mass has
shown positive association with BMD due to increased mechanical loading and the release of
osteogenic hormones from adipose tissue [26]. The production of androgens is higher in obese
than in normal weight women [27]. However, fat mass also produce inflammatory cytokines,
which may negatively influence BMD [28]. Skeletal muscle mass has consistently been associ-
ated with increased BMD in all women due to the mechanical forces on bone during muscle
activity [4,29]. A positive relationship between all body composition parameters and BMD at
spine and hip regions were documented in our study and in another SA study in healthy black
and white women [30]. A beneficial effect of both increased fat and lean mass on BMD mainte-
nance was thus noted irrespective of site and ethnicity.
A low/normal BMI was present in fifty percent of osteoporotic women in sharp contrast
with the total cohort in whom 85% were obese. Low body weight is a well-established risk fac-
tor for OP in breast cancer patients and also reflects in our study [16,31]]. However, over-
weight and obese BMI did not preclude OP in this cohort.
Low vitamin D is a known risk factor for osteoporosis due to the associated negative cal-
cium balance and compensatory secondary hyperparathyroidism with increased bone resorp-
tion [32–34]. The vast majority of our study participants (93%) had insufficient or deficient
vitamin D levels, an extremely high and concerning figure. A marked seasonal variation in
vitamin D3 production was previously documented in Cape Town, with very little being
formed during the winter months [35]. Increased skin pigment and obesity are well known
risk factors for decreased cutaneous vitamin D production, both present in the majority of our
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study subjects. Mean Vitamin D levels did not, against expectation, differ amongst the BMD
subcategories (p = 0.290). This may be explained by the almost universal Vitamin D insuffi-
ciency in study participants.
The American Society of Clinical Oncology considers AI-therapy as the gold standard treat-
ment for hormone-receptor-positive breast cancer. Baseline assessment of bone health (incor-
porating a BMD assessment), timeously identifies women at risk of fracture and ensures
appropriate preventative strategies. Fragility fractures, with its associated morbidity and even
mortality, may significantly impact on the quality of life of AI-treated individuals.
Conclusions drawn from this study are limited by the small sample size of 101 women.
Data obtained nonetheless contributes to the limited knowledge pool regarding the baseline
bone health of South African postmenopausal women of diverse ethnicity with breast cancer.
Another limitation of this work is the absence of a healthy control group. Data derived from
this study are thus not able to delineate differences in bone health between breast cancer par-
ticipants and healthy postmenopausal women. Our data, however, does argue for optimal
assessment of bone health, including a BMD, in postmenopausal women of Mixed Ancestry
considered for therapy with potential adverse bone effects. Conversely, the strength of our
study is that densitometric data were obtained by making use of a single, very experienced den-
sitometrist that positively impacts on the validity of both our body composition and BMD
data.
Conclusion
A significant 32% of postmenopausal women considered for AI therapy fulfilled criteria for
bone protection. Data obtained in this study emphasizes the absolute need for bone risk assess-
ment in all postmenopausal women with breast cancer who are considered for AI therapy.
Valuable information regarding the relationship between body composition variables and
bone health of postmenopausal women of Mixed Ancestry residing in the Western Cape Prov-
ince of South Africa was generated. Improved insights into ethnic variations of bone health,
provided by studies such as ours, will enable preventive approaches to osteoporosis for post-
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